ClinicalTrials.gg
CompletedNCT00544440Updated Jul 17, 2014Results posted

An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma

A Phase 2 interventional study of Abiraterone acetate and Prednisone in Prostate Neoplasms, sponsored by Janssen Research & Development, LLC. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-17.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
57
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Enrollment
48th of 98
57 · median 56
Started
2007
with 3 others
Phase 2
59 of 98
9 open now
Registered
5th of 98
by date
Lead sponsor
13 of 98
Janssen Research & Development, LLC

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 48th largest by enrollment, is one of 4 that started in 2007, is one of 59 in phase 2, and was the 5th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effect of abiraterone acetate on levels of androgens and steroid metabolites in bone marrow plasma of patients with metastatic castration-resistant prostate cancer (CRPC).

Read the detailed description

This is a single-center, open-label (identity of assigned study drug will be known) study investigating the effect of abiraterone acetate on levels of testosterone and dihydrotestosterone (DHT) in bone marrow plasma of patients with metastatic CRPC and evaluating the difference in bone marrow androgen levels between patients with and without serum prostate specific antigen (PSA) decline. Approximately 60 medically or surgically castrated male patients with metastatic CRPC will be enrolled. The study will consist of screening, treatment, and follow-up periods. Patients will be treated orally (by mouth) with abiraterone acetate 1000 mg daily and prednisone 5 mg twice a day until clinical disease progression. Follow-up will continue until the patient dies, is lost to follow-up or withdraws informed consent. Bone marrow aspirates will be collected at Week 1 (predose), Week 9, and the final study visit. Safety will be monitored throughout the study.

03

Conditions studied

  • Prostate Neoplasms

Browse trials for

Keywords

  • Prostate neoplasms
  • Prostate cancer
  • Castration-resistant prostate cancer
  • Abiraterone acetate
  • CB7630
  • Prednisone
  • Testosterone
  • Bone marrow
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven adenocarcinoma of the prostate
  • (ECOG) performance status \<=2 ( Performance Status >=50%)
  • Serum testosterone levels \<50ng/ml
  • Ongoing gonadal androgen deprivation therapy with luteinizing hormone-releasing hormone (LHRH) analogues or orchiectomy (patients, who have not had an orchiectomy, must be maintained on effective LHRH analogue therapy for the duration of the study)
  • Progression of disease despite androgen ablation (either documented osseous or soft tissue disease progression or by prostate specific antigen [PSA] criteria progression)
  • Progressive disease is defined by PSA evidence (PSA level of at least 5 ng/ml which has risen on at least 2 successive occasions, at least 2 weeks apart)
  • Presence of metastatic bone disease
  • Discontinue diethylstilbestrol or treatment for >=4 weeks and for antiandrogens >6 weeks
  • Antiandrogen withdrawal: patients who are receiving an antiandrogen as part of primary androgen ablation must demonstrate disease progression following discontinuation of antiandrogen (disease progression after antiandrogen withdrawal is defined as 2 consecutive rising PSA values, obtained at least 2 weeks apart, or documented osseous or soft tissue progression)
  • For patients receiving flutamide, at least one of the PSA values must be obtained 4 weeks or more after flutamide discontinuation
  • For patients receiving bicalutamide or nilutamide, at least one of the PSA values must be obtained 6 weeks or more after antiandrogen discontinuation
  • Adequate adrenal function
  • Laboratory values within protocol -defined parameters
  • No evidence of chronic or acute disseminated intravascular coagulation or bleeding tendency and no angina at rest
  • Agrees to protocol-defined use of effective

Exclusion criteria

Exclusion Criteria:

  • Histologic variants other than adenocarcinoma in the primary tumor
  • More then 2 different prior chemotherapeutic regimens for prostate cancer
  • Abnormal liver function
  • Therapy with other hormonal therapy, including any dose of megestrol acetate (Megace), Ketoconazole, finasteride (Proscar), dutasteride (Avodart) any herbal product known to decrease PSA levels (eg, Saw Palmetto and PC-SPES), or any systemic within 4 weeks prior to first dose of study drug
  • Active infection or intercurrent illness that are not controlled
  • Unstable angina, myocardial infarction within the previous 6 months, or use of ongoing maintenance therapy for life-threatening ventricular arrhythmia, uncontrolled hypertension, (NYHA) Class III or IV congestive heart failure
  • Prior radiation therapy completed \<4 weeks or single fraction of palliative radiotherapy within 14 days prior to first dose of study drug
  • Any currently active second , other than non-melanoma skin cancer
  • Active psychiatric illnesses/social situations that would limit compliance with protocol requirements
  • Active or uncontrolled disease that may require corticosteroid therapy during study
  • Severely compromised immunological state, including being positive for the (HIV)
  • Acute or chronic or C
  • Initiation of bisphosphonate therapy within 4 weeks prior to first dose of study drug
  • Long syndrome or bundle branch block or hemiblock or other history of life-threatening arrhythmia (unless the patient has been effectively treated for it and is considered stable)
  • Known
  • History of pituitary or adrenal dysfunction
  • History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug
  • Prior therapy with abiraterone acetate
  • Any acute toxicities due to prior chemotherapy and/or radiotherapy that have not resolved to a (version 3) grade of \<=1
  • Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Abiraterone acetate plus prednisone

    Patients will be treated orally with abiraterone acetate 1000 mg daily and prednisone 5 mg twice a day until clinical disease progression.

    Drug: Abiraterone acetate · Drug: Prednisone

Interventions

  • Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily

  • Prednisone 5 mg tablet taken orally twice daily

06

What researchers measure

Primary outcomes

  1. Number of Participants With Detectable Bone Marrow Testosterone Level (>1 Picograms/Mililiter)

    Time frame: Baseline (predose Week 1 Day 1) and Week 8

  2. Number of Participants With Detectable Bone Marrow Dihydrotestosterone (DHT) Level (>9 Picograms/Mililiter)

    Time frame: Baseline (predose Week 1 Day 1) and Week 8

  3. Difference in Bone Marrow Testosterone Levels Between Participants With and Without Serum Prostate Specific Antigen Decline

    Time frame: Week 8

Secondary outcomes

  1. Number of Participants With Change in Markers of Bone Metabolism

    Time frame: Week 8

07

Results

Posted Nov 1, 2013

Participant flow

Participant flow — Overall Study
MilestoneAbiraterone Acetate
Started57
Completed0
Not completed57
Withdrew: Other1
Withdrew: Adverse event1
Withdrew: Withdrawal by subject2
Withdrew: Subject non-compliance1
Withdrew: Progressive disease47
Withdrew: Other5

Outcome measures

PrimaryNumber of Participants With Detectable Bone Marrow Testosterone Level (>1 Picograms/Mililiter)
Time frame:
Baseline (predose Week 1 Day 1) and Week 8
Reported as:
Number · Number of Participants
Number of Participants With Detectable Bone Marrow Testosterone Level (>1 Picograms/Mililiter)
Number of ParticipantsAbiraterone Acetate
Baseline (predose Week 1 Day 1) (n=49)0
Week 8 (n=44)0
PrimaryNumber of Participants With Detectable Bone Marrow Dihydrotestosterone (DHT) Level (>9 Picograms/Mililiter)
Time frame:
Baseline (predose Week 1 Day 1) and Week 8
Reported as:
Number · Number of Participants
Number of Participants With Detectable Bone Marrow Dihydrotestosterone (DHT) Level (>9 Picograms/Mililiter)
Number of ParticipantsAbiraterone Acetate
Baseline (predose Week 1 Day 1) (n=49)2
Week 8 (n=44)2
PrimaryDifference in Bone Marrow Testosterone Levels Between Participants With and Without Serum Prostate Specific Antigen Decline
Time frame:
Week 8

No measurements were reported for this outcome.

SecondaryNumber of Participants With Change in Markers of Bone Metabolism
Time frame:
Week 8

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abiraterone Acetate—29/57 (50.9%)56/57 (98.2%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventAbiraterone Acetate
Back painMusculoskeletal and connective tissue disorders7/57
PneumoniaInfections and infestations5/57
DyspnoeaRespiratory, thoracic and mediastinal disorders5/57
Abdominal painGastrointestinal disorders4/57
AnaemiaBlood and lymphatic system disorders3/57
Disease progressionGeneral disorders3/57
FatigueGeneral disorders3/57
AnorexiaMetabolism and nutrition disorders3/57
ArthralgiaMusculoskeletal and connective tissue disorders3/57
HypotensionVascular disorders3/57
Most frequent other events
Showing 10 of 60
Most frequent other events
EventAbiraterone Acetate
HyperglycaemiaMetabolism and nutrition disorders47/57
FatigueGeneral disorders36/57
Blood alkaline phosphatase increasedInvestigations36/57
AnaemiaBlood and lymphatic system disorders30/57
HypoalbuminaemiaMetabolism and nutrition disorders26/57
HypertensionVascular disorders24/57
Back painMusculoskeletal and connective tissue disorders23/57
ArthralgiaMusculoskeletal and connective tissue disorders22/57
Oedema peripheralGeneral disorders20/57
HypokalaemiaMetabolism and nutrition disorders20/57

Baseline characteristics

Age, Continuous
Age, Continuous(years)Abiraterone Acetate
Mean69.1 ± 8.93
Sex: Female, Male
Sex: Female, Male(Participants)Abiraterone Acetate
Female0
Male57
08

Study locations

1 site
  • Houston, Texas, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2007
First posted
Oct 16, 2007
Start
Oct 2007
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results first posted
Nov 1, 2013
Last update
Jul 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00544440
Responsible party
Sponsor
First posted
Oct 16, 2007
Start date
Oct 2007
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
Nov 1, 2013
Last update
Jul 17, 2014

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone Acetate

Start the discussion